Dr Priscilla Brastianos, page-118

@needle thanks for the article and very good assessment for newbies on here!

This paragraph intrigues me

“More than 50% of brain metastases have different drivers than the primary tumor,” said Dr. Brastianos, citing her work and the work of others. It was this observation that led to a pilot study of a therapy personalized for driver mutations of brain metastases in 15 heavily pretreated patients with a mix of primary tumor histologies. Eight achieved intracranial benefit, defined as complete response, partial response, or stable disease, meeting the primary endpoint.

It would be interesting to understand the pilot study drugs and whether Paxalisib was part of that? Do you have any knowledge of this? Thanks